Women's POTS patented medical grade compression leggings and shorts
A collection page of Supacore
About
Supacore’s Coretech® compression leggings are the only medically listed and patented compression leggings designed to help manage symptoms of Postural Orthostatic Tachycardia Syndrome (POTS) . Engineered using advanced body-mapping technology, Coretech targets the pelvis and core —critical zones for both circulatory regulation and postural stability . Unlike standard leg-only compression garments, Coretech’s patented design supports the body’s deep stabilising system, helping improve both blood flow and physical stability—two areas where POTS patients often struggle. How Coretech® Compression Supports POTS Management Improves Circulation to the Brain: Graduated compression encourages venous return and enhances blood flow to the heart and brain, helping reduce common symptoms like dizziness, light-headedness, and fatigue upon standing. Reduces Blood Pooling in the Lower Body: Coretech’s pelvic and lower-limb compression helps prevent excessive blood from pooling in the legs and abdomen—key contributors to fainting, tachycardia, and orthostatic intolerance. Stabilises the Pelvis and Core: By reinforcing the deep stabilising muscles, Coretech reduces the physical effort required to maintain upright posture. This pelvic/core support helps POTS patients conserve energy, improve balance, and manage symptoms during prolonged standing or movement . Eases Autonomic Load: With improved circulatory efficiency and musculoskeletal support, Coretech can help reduce the stress placed on a dysregulated autonomic nervous system. Minimises Inflammation and Swelling: Compression assists lymphatic flow and tissue recovery, helping to reduce systemic inflammation that may exacerbate symptoms. Relieves Muscle and Joint Pain: Targeted compression around the hips, lower back, and legs supports alignment and relieves pressure on overworked muscles and joints, helping maintain mobility and comfort. Supacore Coretech® leggings are registered with the Therapeutic Goods Administration (TGA) as